A fascinating new study just published online today in @NatureMedicine reports an extraordinary case of an individual carrying the PSEN2 (p.Asn141Ile) mutation—a known driver of dominantly inherited Alzheimer’s disease (DIAD)—who remained cognitively healthy well into his mid-70s. This is nearly 18 years past the expected age of onset. The study combines longitudinal clinical assessments, neuroimaging, genetic analysis, and proteomics to uncover the mechanisms underlying his remarkable resistance to Alzheimer’s (nature.com/articles/s41591-0…) 🎉🧬🧠🔍 The PSEN2 p.Asn141Ile mutation causes excessive production of amyloid-beta, resulting in amyloid plaques—one of the hallmarks of Alzheimer’s disease. While this individual’s brain was filled with amyloid deposits, the expected cognitive decline and dementia never materialized. Tau pathology, another key feature of Alzheimer’s, was restricted to the occipital lobe, a brain region associated with visual processing but not typically involved in Alzheimer’s-related cognitive decline. This rare localized tau pattern may explain the individual’s cognitive preservation and highlights the potential of tau-targeted therapies. Over the course of 10 years of follow-up, the individual’s Cognitive Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) scores remained normal (CDR = 0; MMSE = 30) for the subsequent four (2014, 2016, 2018 and 2021) assessments performed over 10 years, including the most recent evaluation in 2021 at age 71. Genetic analysis in this study utilized whole-genome sequencing (WGS) and whole-exome sequencing (WES) on family members, including the exceptional resilience mutation carrier, to identify rare and common coding variants associated with resilience to Alzheimer’s disease. Segregation analysis prioritized variants that were exclusive to the resilience carrier or specific subgroups within the family. Several unique variants were identified within the 17q21.31 MAPT-H1 haplotype region, along with potential protective variants in AD-associated genes such as TREM2 and MAPT. Proteomic profiling in this study identified an abundance of heat shock proteins, suggesting a potential adaptive stress response. Remarkably, this individual had prolonged exposure to high temperatures while working as a mechanic on a naval ship, requiring frequent cooling with water to prevent overheating. The heat-shock response triggered by such extreme conditions may have contributed to his resistance to neurodegeneration. These results suggest that a combination of genetic factors, environmental exposures, and enriched biological pathways may contribute to the delayed onset of AD in this individual. The imaging data tell a powerful story. PET scans showed elevated amyloid burden with a PiB cortical SUVR (Z-scored relative to non-carriers aged 50 years old and above) of ~3.6, far above the threshold for abnormal amyloid deposition. However, tau PET imaging revealed that tau pathology remained focal and asymmetric, concentrated in the occipital lobe, rather than spreading to key regions like the medial temporal lobe or parietal cortex, which are typically affected in Alzheimer’s disease. This restricted tau spread contrasts sharply with the usual progression seen in mutation carriers, where tau accumulation is tightly linked to cognitive decline. MRI scans showed that hippocampal volume declined only modestly over the 10 years of follow-up, consistent with normal aging rather than Alzheimer’s atrophy. FDG PET scans showed localized hypometabolism in areas with focal tau deposition, yet metabolic activity remained normal in other key brain regions. From a broader perspective, this study raises questions about the amyloid hypothesis—the long-standing theory that amyloid plaques are the primary driver of Alzheimer’s. The case suggests that limiting tau deposition and spread may be more critical in preventing cognitive decline, even in the presence of substantial amyloid burden. This finding could reshape the focus of Alzheimer’s research and clinical trials, emphasizing tau-targeted therapies. The proteomic analysis further revealed significant differences in this individual’s plasma proteome and cerebrospinal fluid (CSF) compared to typical PSEN2 carriers. Notably, pathways related to protein folding, synaptic function, and oxidative stress were enriched, with multiple heat shock proteins showing elevated expression. These proteins may play a crucial role in maintaining cellular homeostasis and protecting against protein misfolding, a common feature of neurodegenerative diseases. In summary, this study opens exciting new avenues for Alzheimer’s research by identifying potential protective genetic and proteomic factors. It underscores the importance of studying rare resilience cases to uncover new therapeutic strategies. Restricting tau spread may prove to be a transformative approach in delaying or preventing dementia. The insights gained from this individual offer hope for developing precision medicine strategies for Alzheimer’s disease. Huge congratulations to the research team—Jorge J. Llibre-Guerra, M. Victoria Fernandez, Nelly Joseph-Mathurin, @shijbian, Kathleen Carter, @ccrugom, Erik C. B. Johnson, @RandallBateman3, and many others—along with the Dominantly Inherited Alzheimer Network (DIAN), the study participant and his family members, whose dedication continues to pave the way for life-changing discoveries. [About this post: this post is based on a summary of Llibre-Guerra, J.J., Fernandez, M.V., Joseph-Mathurin, N. et al. Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia. Nat Med (2025). doi.org/10.1038/s41591-025-0…]